METI will hold GGX Finance Summit
27.10.2025 07:30:00 CET | Business Wire | Press Release
On November 5 (Wed), the Ministry of Economy, Trade and Industry (METI) will hold the GGX Finance Summit at The Capitol Hotel Tokyu and on-line. In order to further develop discussions on transition finance, industry decarbonization, and other topics related to how business and finance contribute to decarbonization, we will promote mutual cooperation between the government, business, and financial sectors, and hold discussions to lead the international rule-making process to achieve both emission reductions and economic growth.
Outline of GGX Finance Summit
Date: November 5th, 2025 10:00-16:45 (JST, GMT+9:00)
Venue: The Capitol Hotel Tokyu (Tokyo) (2-10-3, Nagata-cho, Chiyoda-ku, Tokyo 100-0014, Japan)
Organizer: Ministry of Economy, Trade and Industry (METI), GX Acceleration Agency
Co-organizer: World Business Council for Sustainable Development (WBCSD), TCFD Consortium
Format: Hybrid (On-site and on-line)
Language: Japanese/English (with English/Japanese simultaneous interpretation)
Press Registration
Please complete your registration by accessing the official website below.
[ Registration Site ] *Please proceed your registration from the link in the official website.
https://ggxf-summit.go.jp/indexEn.html
[ Deadline of the registration ]
- Writer / Still Camera / Video Camera Pre-registration deadline (Onsite Attendance): 29 October, 2025 (Wed.), 17:00 JST
- Writer Pre-registration deadline (Online Attendance): 3 November, 2025 (Mon.) JST
*As the summit date approaches, the attendance certificate for "Onsite Attendance" or the viewing link for "Online Attendance" will be sent via email.
Program
- 10:00-10:10 Opening Remarks
TSUTSUI Yoshinobu (Chairperson, GX Acceleration Agency)
ITO Sadanori (Director-General, GX Policy Group, Ministry of Economy, Trade and Industry (METI))
- 10:10-10:20 Keynote Speech1 “How do we accelerate Japan’s GX?”
As COO of the GX Acceleration Agency and a member of the GX Implementation Council, Mr. Shigetake will speak about Japan's GX initiatives and challenges, how we are working to overcome these challenges, and what must be done now for the future.
SHIGETAKE Naoki (COO, GX Acceleration Agency)
- 10:20-11:20 Panel Discussion1 "Global trend towards carbon neutrality and expectations for Japan's GX (Discussion by GXA Global Advisory Council Members)"
In this panel, international experts will share their views on the latest global trends toward decarbonization and discuss expectations and prospects for Japan's GX initiative, which will achieve decarbonization with economic growth and strengthened industrial competitiveness.
[ Moderator ]
TAKADA Hideki (Director (Finance and Sustainability), GX Acceleration Agency)
[ Panelist ]
Nicholas Pfaff (Deputy CEO, International Capital Market Association (ICMA))
Robert Youngman (Team Leader, Green Finance and Investment, Organisation for Economic Co-operation and Development)
Sherry Madera (Chief Executive Officer, CDP)
Amit Bouri (Chief Executive Officer and Co-Founder, Global Impact Investing Network)
Sean Kidney (CEO and Co-founder, Senior Leadership Team, Climate Bonds Initiative)
Mary L. Schapiro (Vice Chair for Global Public Policy at Bloomberg L.P., where she also serves as Special Advisor to the Founder and Chairman and Vice Chair of the Glasgow Financial Alliance for Net Zero (GFANZ))
- 11:30-12:15 Panel Discussion2 “Expanding the Base of Financiers in Japan's Transition Finance"
This panel will explore measures and prospects for expanding the base of transition finance providers in Japan to support the massive capital demand for carbon neutrality by 2050.
[ Moderator ]
YOSHITAKA Mari (Representative Director, General Incorporated Association Virtue Design / Steering Committee Member, Representative Director、GX Acceleration Agency)
[ Panelist ]
TANAKA Junichi (General Manager, Responsible Investment, Investment Planning Department, Sumitomo Life Insurance Company)
II Sachie (Sustainability Chief Strategist, Sustainable Business Promotion Department, Mizuho Financial Group, Inc.)
SHIOMURA Kenji (Fellow/ Executive Sustainability Advisor, Research Division, Daiwa Institute of Research Ltd.)
- 13:30-14:00 Guest Remarks
HANZAWA Junichi (Chairperson, Japanese Bankers Association)
UCHIDA Kazuto (President, Government Pension Investment Fund)
- 14:00-15:00 Panel Discussion3 “How to promote transition finance in Asia"
Transitions in emerging countries, particularly in Asia, as a center of global economic growth, is crucial for global decarbonization. This panel will examine the possibilities and challenges of transition finance in Asia.
[ Moderator ]
HAYASHI Reiko (Deputy President, BofA Securities Japan Co., Ltd.)
[ Panelist ]
Pradeep Tharakan (Director for Energy Transition, Asian Development Bank)
YAMASAKI Ryo (Special Advisor, Energy Investment Unit, Office Of The Chief Energy Economist, International Energy Agency)
ISHIKAWA Tomohiro (Chief Regulatory Engagement Officer, Sustainable Business Division, Mitsubishi UFJ Financial Group, Inc.)
MIURA Tai (Deputy General Manager, Power And Infrastructure Services Division, Marubeni Corporation)
- 15:15-15:30 Keynote Speech2 “Toward the Future of Climate Disclosure”
This keynote will focus on how sustainability-related disclosures can be effectively linked to investment rather than disclosure for its own sake.
ITO Kunio (Director of Hitotsubashi CFO Education and Research Center/ Chair of the TCFD Consortium)
- 15:30-16:30 Panel Discussion4 "How to build GX Market through enhanced disclosure"
To expand GX investment, GX value should be fairly evaluated in the market. This panel will discuss how to assess reduction efforts across the entire value chain increasing disclosure requirement related to climate change.
[ Moderator ]
KAJIWARA Atsuko (Managing Director, Financial Services Unit, Deloitte Tohmatsu Risk Advisory LLC)
[ Panelist ]
OSHIDA Shunsuke (Head Of Credit Research, Japan, Credit Research, Manulife Investment Management)
TEZUKA Hiroyuki (Fellow, JFE Steel Corporation)
Marvin Henry (Director, Climate Action, World Business Council for Sustainable Development)
NUMA Tsuyoshi (Manager, Finance, Kawasaki Heavy Industries, Ltd.) and more
- 16:30-16:45 Closing Remarks
Nicholas Pfaff (Deputy CEO, International Capital Market Association (ICMA))
*The above programs and speakers may be subject to change at the discretion of the organizer.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251026983096/en/
Contacts
Contact information for inquiries
GGX Finance Summit 2025 Press Registration Desk (E-mail:
ggxf-summit-press@convention.co.jp)
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom